ACTIVE

BIOMEDICS

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result64,8 k €-33,2 %over 1 year
Gross margin196,2 k €-15,3 %over 1 year
Equity234 k €+0,4 %over 1 year
Workforce1,8 ETP-5,3 %over 1 year

Identity

Source · BCE/KBO

BIOMEDICS is a Public limited company incorporated in 1992. Its main activity is: Pre-primary education. Its registered office is in Wervik. It employs on average 1,8 ETP workers (FTE).

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0448.523.941
Incorporation
30/10/1992
Legal form
Public limited company
Registered office
Menenstraat 104
8940 Wervik · FlandreSee on map
Contributed capital
62 000,00 €
Latest accounts
31/12/2025
Average workforce
1,8 ETP
Joint committees (3)
  • 305
  • 330
  • 33004
Signals
ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debts

Financials

Source · NBB, 20 filings

Trend over 20 financial years

20252024202320222021
Income statement
Gross margin196,2 k €231,6 k €254,8 k €251 k €249,2 k €
EBITDA87,8 k €129,6 k €159,8 k €148,8 k €166,9 k €
Operating result84,6 k €126,9 k €157,1 k €146,3 k €164,1 k €
Net result64,8 k €97,1 k €120,1 k €113,5 k €125,1 k €
Balance sheet
Equity234 k €233,1 k €232 k €231,9 k €230,4 k €
Total assets312,7 k €344,7 k €367,8 k €392,4 k €367,3 k €
Cash193,7 k €239,6 k €267,9 k €261,4 k €276,2 k €
Debts78,7 k €111,6 k €135,8 k €160,4 k €136,8 k €
Other
Workforce1,8 ETP1,9 ETP1,9 ETP1,8 ETP1,8 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 500 k€ and 1 M€
See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

2 active · 8 ended

Active mandates

DEBA PHARMA

Managing director · since 27 mai 2022 · until 27 mai 2028 · 0434.737.865

Represented by DEJONGHE JOHAN

Active
FACTIS

Managing director · since 27 mai 2022 · until 27 mai 2028 · 0430.812.434

Represented by DEYLGAT ELS

Active

Ended mandates

DEBA PHARMA

Managing director · 0434.737.865

Represented by Johan DEJONGHE

Ended
DEBA PHARMA

Managing director · 0434.737.865

Represented by Johan DEJONGHE

Ended
DEBA PHARMA

Managing director · 0434.737.865

Represented by Johan DEJONGHE

Ended
FACTIS

Managing director · 0430.812.434

Represented by Els DEYLGAT

Ended

Full financial information

Source · NBB
202520242023202220212020
Type of accountAbridged modelAbridged modelAbridged modelAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202101/01/2020
Closing of the financial year31/12/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date25/07/202623/06/202517/06/202411/07/202315/06/202223/06/2021
General meeting29/06/202630/05/202531/05/202416/06/202327/05/202228/05/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for 7 days

Annual accounts filings

Source · NBB, 20 filings
ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202529/06/202625/07/2026DutchPDF
Abridged model31/12/202430/05/202523/06/2025DutchPDF
Abridged model31/12/202331/05/202417/06/2024DutchPDF
Abridged model31/12/202216/06/202311/07/2023DutchPDF
Abridged model31/12/202127/05/202215/06/2022DutchPDF
Abridged model31/12/202028/05/202123/06/2021DutchPDF
Abridged model31/12/201929/05/202016/06/2020DutchPDF
Abridged model31/12/201831/05/201919/06/2019DutchPDF
Abridged model31/12/201725/05/201801/06/2018DutchPDF
Abridged model31/12/201626/05/201721/06/2017DutchPDF
Abridged model31/12/201527/05/201614/06/2016DutchPDF
Abridged model31/12/201429/05/201515/06/2015DutchPDF
Abridged model31/12/201330/05/201404/06/2014DutchPDF
Abridged model31/12/201231/05/201314/06/2013DutchPDF
Abridged model31/12/201122/06/201220/07/2012DutchPDF
Abridged model31/12/201024/06/201120/07/2011DutchPDF
Abridged model31/12/200928/05/201025/06/2010DutchPDF
Abridged model31/12/200830/06/200920/07/2009DutchPDF
Abridged model31/12/200730/05/200802/06/2008DutchPDF
Abridged model31/12/200625/05/200729/05/2007DutchPDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 500 k€ and 1 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

2 active · 8 ended

Active mandates

DEBA PHARMA

Managing director · since 27 mai 2022 · until 27 mai 2028 · 0434.737.865

Represented by DEJONGHE JOHAN

Active
FACTIS

Managing director · since 27 mai 2022 · until 27 mai 2028 · 0430.812.434

Represented by DEYLGAT ELS

Active

Ended mandates

DEBA PHARMA

Managing director · 0434.737.865

Represented by Johan DEJONGHE

Ended
DEBA PHARMA

Managing director · 0434.737.865

Represented by Johan DEJONGHE

Ended
DEBA PHARMA

Managing director · 0434.737.865

Represented by Johan DEJONGHE

Ended
FACTIS

Managing director · 0430.812.434

Represented by Els DEYLGAT

Ended

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Other28/12/2023
    STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …)
    PDF
  • Mandates06/07/2022
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates23/06/2016
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates03/09/2010
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Capital / shares26/10/2004
    KAPITAAL - AANDELEN - ALGEMENE VERGADERING - STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …)
    PDF
  • Mandates12/07/2004
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates28/03/2003
    ONTSLAGEN - BENOEMINGEN
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 202564,8 k €↓
  2. 2024
    Annual accounts 202497,1 k €↓
  3. 2023
    Annual accounts 2023120,1 k €↑
  4. 2022
    Annual accounts 2022113,5 k €↓
  5. 2021
    Annual accounts 2021125,1 k €↓
  6. 2020
    Annual accounts 2020152,7 k €↓
  7. 2019
    Annual accounts 2019175 k €↓
  8. 2018
    Annual accounts 2018185,9 k €↑
  9. 2017
    Annual accounts 2017157,7 k €↓
  10. 2016
    Annual accounts 2016181,3 k €↑
  11. 2015
    Annual accounts 201594,5 k €↑
  12. 2014
    Annual accounts 201494,2 k €↑
  13. 2013
    Annual accounts 201387 k €↑
  14. 2012
    Annual accounts 201281,3 k €↓
  15. 2011
    Annual accounts 201182,1 k €↑
  16. 2010
    Annual accounts 201066,2 k €↓
  17. 2009
    Annual accounts 200969,2 k €↓
  18. 2008
    Annual accounts 200877,7 k €↓
  19. 2007
    Annual accounts 200789,8 k €↓
  20. 2006
    Annual accounts 200693,8 k €
  21. 30/10/1992
    IncorporationPublic limited company